Infections Management in the Lung Transplant Setting in Italy: A Web-Survey
- PMID: 39791921
- PMCID: PMC12017298
- DOI: 10.1111/tid.14413
Infections Management in the Lung Transplant Setting in Italy: A Web-Survey
Abstract
Introduction: Infections significantly impact morbidity and mortality in lung transplant (LuTx) recipients. This survey focused on documenting current practices regarding the prevention and management of infections in LuTx in Italy.
Methods: A 52-question survey was administered online in the period from December 1, 2023, to January 31, 2024, assessing center characteristics, Tx team organization, microbiological investigations, infection prevention, and management. All Italian LuTx centers were invited to participate.
Results: Nine out of 10 Italian LuTx centers answered. Most centers (6/9, 67%) performed LuTx only on adults. Chronic infection or colonization by Mycobacterium abscessus and Burkholderia cenocepacia is considered a contraindication to LuTx in five and two centers, respectively. For cytomegalovirus D+/R- patients, prophylaxis is used in six centers (67%), with a variable duration from 3 to 12 months. Two centers also use IgG. Three centers (33%) use a pre-emptive strategy. Four centers (45%) screen for Human herpesvirus 8 infection. Regarding antibiotic prophylaxis, most centers (6/9, 67%) utilise a dual regimen of anti-pseudomonal penicillin plus glycopeptide. The two most common durations of antibiotic prophylaxis were 72 h and 7 days, each reported by two centers (22%). Targeted prophylaxis against fungal infections is employed by a minority of centers (4/9, 44%). Inhaled amphotericin B is the most common antifungal, used as targeted prophylaxis (2/4, 50%) and universal prophylaxis (2/5, 40%). Almost all centers (8/9, 89%) involve the Tx infectious diseases specialist in the recipient management since the pre-listing period.
Conclusion: There is considerable heterogeneity in infection management among Italian LuTx centers. Establishing a shared platform for data collection and outcome evaluation is essential to improve infection management.
Keywords: donor‐derived infections | lung transplant | prophylaxis.
© 2024 The Author(s). Transplant Infectious Disease published by Wiley Periodicals LLC.
Conflict of interest statement
The authors declare no conflicts of interest.
References
-
- Yusen R. D., Edwards L. B., Kucheryavaya A. Y., et al., “The Registry of the International Society for Heart and Lung Transplantation: Thirty‐first Adult Lung and Heart‐lung Transplant Report ‐ 2014; Focus Theme: Retransplantation,” Journal of Heart and Lung Transplantation 33 (2014): 1009–1024, 10.1016/j.healun.2014.08.004. - DOI - PubMed
MeSH terms
Substances
Grants and funding
- Ministero della Salute, Ricerca Corrente Funds 2023
- Italian Ministry of Health
- Ricerca Corrente
- PE00000007/NextGenerationEU - MUR - National Recovery and Resilience Plan, Mission 4, Component 2 Investment 1.3 - Extended Partnership initiative on Emerging Infectious Diseases INF-ACT
- CUP B73C22001230006/NextGenerationEU - MUR - National Recovery and Resilience Plan, Mission 4, Component 2 Investment 1.3 - Extended Partnership initiative on Emerging Infectious Diseases INF-ACT
LinkOut - more resources
Full Text Sources
Medical